Literature DB >> 11799260

Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications.

C H Chang1, Y M Wang, A H Yang, S S Chiang.   

Abstract

BACKGROUND/AIM: Nephropathy after ingestion of Chinese herbs is known as a rapidly progressive form of interstitial renal fibrosis after a slimming regimen containing aristolochic acid that was identified first in Belgium. Intake of traditional Chinese herbal medicines is very popular in Taiwan. So we looked for similar cases in our hospital.
METHODS: From 1994 to 1998, we observed 20 Taiwanese patients who underwent renal biopsy for rapidly progressive renal failure of unknown origin. The medical history of these patients gave no clue to the origin of renal impairment, except for the administration of Chinese herbs before the development of renal failure in all cases.
RESULTS: Although these patients took herbal medications from various sources for different purposes, their renal biopsy specimens showed strikingly similar histological patterns: extensive paucicellular interstitial fibrosis and tubular atrophy, but the glomeruli were apparently intact. They also had similar clinical features, such as a nearly normal blood pressure, obvious anemia, insignificant edema, low-grade proteinuria, and glucosuria. The renal function declined rapidly in most cases; 15 patients underwent dialysis within 3 months of renal biopsy, and 7 patients received emergency dialysis when they first came to our hospital. On clinical and morphological grounds, the nephropathy in our patients appears similar to Chinese herb nephropathy.
CONCLUSIONS: Because of the diversity of the herbal regimens used, in addition to aristolochic acid, other unidentified phytotoxins may also play a role in this particular disease entity. There is a strong relation between rapidly progressive interstitial renal fibrosis and the consumption of Chinese herbs. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11799260     DOI: 10.1159/000046647

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  14 in total

1.  [Evaluation of renal oxygenation in rats with acute aristolochic acid nephropathy using blood oxygenation level-dependent magnetic resonance imaging].

Authors:  Guixiang Yang; Yingjie Mei; Jian Lü; Quan Tao; Yanqiu Feng; Yikai Xu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

2.  Increased incidence of carcinoma of the tongue in patients with systemic sclerosis.

Authors:  Chris T Derk; Mehmoodur Rasheed; Joseph R Spiegel; Sergio A Jimenez
Journal:  J Rheumatol       Date:  2005-04       Impact factor: 4.666

3.  Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.

Authors:  Kathleen G Dickman; Chung-Hsin Chen; Arthur P Grollman; Yeong-Shiau Pu
Journal:  World J Urol       Date:  2022-07-22       Impact factor: 3.661

4.  Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.

Authors:  Ming-Nan Lai; Shuo-Meng Wang; Pau-Chung Chen; Ya-Yin Chen; Jung-Der Wang
Journal:  J Natl Cancer Inst       Date:  2009-12-21       Impact factor: 13.506

Review 5.  Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.

Authors:  Jean-Pierre Cosyns
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  Factors associated with CKD in the elderly and nonelderly population.

Authors:  Ming-Yen Lin; Yi-Wen Chiu; Chien-Hung Lee; Hui-Yen Yu; Hung-Chun Chen; Ming-Tsang Wu; Shang-Jyh Hwang
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 8.237

7.  Pharmacokinetics of p-Aminohippuric Acid and Inulin in Rabbits with Aristolochic Acid Nephropathy.

Authors:  Chiao-Shih Tseng; Shih-Ming Chen; Shu-Chen Chien; Kuang-Yang Hsu
Journal:  Adv Pharmacol Sci       Date:  2011-06-16

8.  Smad7 protects against chronic aristolochic acid nephropathy in mice.

Authors:  Xiao-Yu Dai; Li Zhou; Xiao-Ru Huang; Ping Fu; Hui-Yao Lan
Journal:  Oncotarget       Date:  2015-05-20

9.  Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003.

Authors:  Shu-Ching Hsieh; I-Hsin Lin; Wei-Lum Tseng; Chang-Hsing Lee; Jung-Der Wang
Journal:  Chin Med       Date:  2008-10-23       Impact factor: 5.455

10.  End-stage renal disease in Taiwan: a case-control study.

Authors:  Su-Ying Tsai; Hung-Fu Tseng; Hsiu-Fen Tan; Yu-Shu Chien; Chia-Chu Chang
Journal:  J Epidemiol       Date:  2009-06-20       Impact factor: 3.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.